Johan Dighed
Director/Miembro de la Junta en PROMIMIC AB .
Perfil
Johan Dighed is currently the Chief Legal Officer & Deputy CEO at Karolinska Development AB.
He is also a Director at Promimic AB, KCIF Fund Management AB, KDev Oncology AB, Modus Therapeutics AB, KD Incentive AB, KDev Investments AB, and AnaCardio AB.
Previously, he worked as the Head-Legal at DSK Hyp AG.
Mr. Dighed graduated from the University of Lund.
Cargos activos de Johan Dighed
Empresas | Cargo | Inicio |
---|---|---|
KAROLINSKA DEVELOPMENT AB | Consejero General | 01/05/2020 |
PROMIMIC AB | Director/Miembro de la Junta | 01/01/2021 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Miembro de la Junta | - |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | - |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | - |
KCIF Fund Management AB | Director/Miembro de la Junta | - |
KD Incentive AB | Director/Miembro de la Junta | - |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Johan Dighed.
Empresas | Cargo | Fin |
---|---|---|
DSK Hyp AG
DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Consejero General | - |
Formación de Johan Dighed.
University of Lund | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
KAROLINSKA DEVELOPMENT AB | Finance |
PROMIMIC AB | Health Technology |
Empresas privadas | 7 |
---|---|
DSK Hyp AG
DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Finance |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Health Technology |
KCIF Fund Management AB | |
KD Incentive AB | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Johan Dighed